Postbiotics Unveiled: Mechanistic Insights and Therapeutic Implications in Obesity.

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 03 | 01 | Page :
    By

    Hari Om,

Abstract

The burgeoning global obesity epidemic necessitates innovative therapeutic approaches, and postbiotics, bioactive compounds arising from microbial fermentation, have emerged as promising contenders in reshaping obesity management. This comprehensive review explores the multifaceted mechanisms by which postbiotics impact obesity, from modulating gut microbiota composition to influencing metabolic pathways and enhancing energy expenditure. The exploration of postbiotics is rooted in a deeper understanding of the gut–brain axis and bidirectional communication between gut microbiota and host physiology in history. Unraveling the intricate mechanisms reveals that postbiotics selectively inhibit undesirable bacteria and demonstrate remarkable modulation of the host’s immune response, neuropeptides involved in appetite regulation, and improvements in insulin sensitivity. The symphony of interactions underscores the potential of postbiotics to address the multifactorial nature of obesity, offering a nuanced and comprehensive strategy. Furthermore, the anti-inflammatory effects of postbiotics resonate throughout the host’s metabolic pathways, influencing immune modulation and improving insulin sensitivity. As clinical evidence supports the efficacy of postbiotics in weight management and improvements in metabolic parameters, considerations for personalized treatment approaches become imperative. Integrating postbiotics into obesity management strategies offers an additional layer of intervention, with healthcare professionals playing a pivotal role in promoting their adoption. Navigating future directions and challenges involves addressing gaps in knowledge, exploring synergies with other therapeutic approaches, and overcoming hurdles in translating postbiotic research into clinical practice. In conclusion, the potential of postbiotics in reshaping obesity treatment is substantial, offering a glimpse into a future where microbial-derived compounds play a pivotal role in promoting health and mitigating the global burden of obesity-related complications.

Keywords: Keywords: Body mass index, clinical studies, insulin resistance, metabolic disorders, probiotics

How to cite this article:
Hari Om. Postbiotics Unveiled: Mechanistic Insights and Therapeutic Implications in Obesity.. Emerging Trends in Metabolites. 2026; 03(01):-.
How to cite this URL:
Hari Om. Postbiotics Unveiled: Mechanistic Insights and Therapeutic Implications in Obesity.. Emerging Trends in Metabolites. 2026; 03(01):-. Available from: https://journals.stmjournals.com/etm/article=2026/view=236603


References

  1. Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18:649–67. doi: 10.1038/S41575-021-00440-6.
  2. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008;32:1720–4. doi: 10.1038/ijo.2008.155.
  3. Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 2014;588:4223–33. doi: 10.1016/j.febslet.2014.09.039.
  4. Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: Current evidence, controversies, and perspectives. Curr Obes Rep. 2020;9:179–92. doi: 10.1007/s13679-020-00379-w.
  5. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: Role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020;123:1127–37. doi: 10.1017/S0007114520000380.
  6. Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, et al. Differences in gut microbiota composition between obese and lean children: A cross-sectional study. Gut Pathog. 2013;5:10. doi: 10.1186/1757-4749-5-10.
  7. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–6. doi: 10.1073/pnas.1005963107.
  8. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, et al. Western diet induces dysbiosis with increased Escherichia coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63:116–24. doi: 10.1136/gutjnl-2012-304119.
  9. Kobyliak N, Falalyeyeva T, Boyko N, Tsyryuk O, Beregova T, Ostapchenko L. Probiotics and nutraceuticals as a new frontier in obesity prevention and management. Diabetes Res Clin Pract. 2018;141:190–9. doi: 10.1016/j.diabres.2018.05.005.
  10. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–71. doi: 10.2337/db11-1019.
  11. Yang JJ, Huang RC. Afterhyperpolarization potential modulated by local [K⁺] o in K⁺ diffusion-restricted extracellular space in the central clock of suprachiasmatic nucleus. Biomed J. 2023;46. doi: 10.1016/j.bj.2022.07.005.
  12. Igarashi M, Morimoto M, Suto A, Nakatani A, Hayakawa T, Hara K, et al. Synthetic dietary inulin, Fuji FF, delays development of diet-induced obesity by improving gut microbiota profiles and increasing short-chain fatty acid production. PeerJ. 2020;8:e8893. doi: 10.7717/peerj.8893.
  13. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PGB, Neyrinck AM, et al. Insight into the prebiotic concept: Lessons from an exploratory, double-blind intervention study with inulin-type fructans in obese women. Gut. 2013;62:1112–21. doi: 10.1136/gutjnl-2012-303304.
  14. Kumar SA, Ward LC, Brown L. Inulin oligofructose attenuates metabolic syndrome in high-carbohydrate, high-fat diet-fed rats. Br J Nutr. 2016;116:1502–11. doi: 10.1017/S0007114516003627.
  15. Chen Q, Liu M, Zhang P, Fan S, Huang J, Yu S, et al. Fucoidan and galactooligosaccharides ameliorate high-fat diet–induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism. Nutrition. 2019;65:50–9. doi: 10.1016/j.nut.2019.03.001.
  16. Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics supplemented with omega-3 fatty acids are more effective for hepatic steatosis reduction in an animal model of obesity. Probiotics Antimicrob Proteins. 2017;9:123–30. doi: 10.1007/s12602-016-9230-1.
  17. Matheus VA, Monteiro LCS, Oliveira RB, Maschio DA, Collares-Buzato CB. Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta-cell and intestinal barrier dysfunctions in prediabetic mice. Exp Biol Med (Maywood). 2017;242:1214–26. doi: 10.1177/1535370217708188.
  18. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa KI, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–505. doi: 10.1172/JCI26498.
  19. Li Y, Liu M, Liu H, Wei X, Su X, Li M, et al. Oral supplements of combined Bacillus licheniformis Zhengchangsheng® and xylooligosaccharides improve high-fat diet-induced obesity and modulate the gut microbiota in rats. Biomed Res Int. 2020;2020:9067821. doi: 10.1155/2020/9067821.
  20. Oh YJ, Kim HJ, Kim TS, Yeo IH, Ji GE. Effects of Lactobacillus plantarum PMO 08 alone and combined with chia seeds on metabolic syndrome and gut health in obese mice. J Med Food. 2019;22:1199–207. doi: 10.1089/jmf.2018.4349.
  21. Li HY, Zhou DD, Gan RY, Huang SY, Zhao CN, Shang A, et al. Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narrative review. Nutrients. 2021;13:3211. doi: 10.3390/nu13093211.
  22. Kamdar K, Khakpour S, Chen J, Leone V, Brulc J, Mangatu T, et al. Genetic and metabolic signals during acute enteric bacterial infection alter the microbiota and drive progression to chronic inflammatory disease. Cell Host Microbe. 2016;19:21–31. doi: 10.1016/j.chom.2015.12.006.
  23. Worthmann A, John C, Rühlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med. 2017;23:839–49. doi: 10.1038/nm.4357.
  24. Ye J, Lv L, Wu W, Li Y, Shi D, Fang D, et al. Butyrate protects mice against methionine–choline-deficient diet-induced non-alcoholic steatohepatitis. Front Microbiol. 2018;9:1967. doi: 10.3389/fmicb.2018.01967.
  25. Ban Q, Cheng J, Sun X, Jiang Y, Guo M. Effect of synbiotic yogurt sweetened with monk fruit extract on lipid levels and hepatic AMPK signaling in type 2 diabetic rats. Food Funct. 2020;11:7696–706. doi: 10.1039/D0FO01860K.
  26. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SEK, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation and adiposity. Gut. 2015;64:1744–54. doi: 10.1136/gutjnl-2014-307913.
  27. Olli K, Salli K, Alhoniemi E, Saarinen M, Ibarra A, Vasankari T, et al. Postprandial effects of polydextrose on satiety hormone responses in obese participants. Nutr J. 2015;14:2. doi: 10.1186/1475-2891-14-2.
  28. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, et al. Dietary resistant starch upregulates GLP-1 and PYY via fermentation in rodents. Am J Physiol Endocrinol Metab. 2008;295:E1160–9. doi: 10.1152/ajpendo.90637.2008.
  29. Karaki SI, Mitsui R, Hayashi H, Kato I, Sugiya H, Iwanaga T, et al. Short-chain fatty acid receptor GPR43 expression in rat intestine. Cell Tissue Res. 2006;324:353–60. doi: 10.1007/s00441-005-0140-x.
  30. Karaki SI, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y, et al. Expression of the short-chain fatty acid receptor GPR43 in the human colon. J Mol Histol. 2008;39:135–42. doi: 10.1007/s10735-007-9145-y.
  31. Yuan X, Chen R, McCormick KL, Zhang Y, Lin X, Yang X. Role of the gut microbiota on the metabolic status of obese children. Microb Cell Fact. 2021;20:54. doi: 10.1186/s12934-021-01548-9.
  32. Cavallari JF, Fullerton MD, Duggan BM, Foley KP, Denou E, Smith BK, et al. Muramyl dipeptide-based postbiotics mitigate obesity-induced insulin resistance via IRF4. Cell Metab. 2017;25:1063–74.e3. doi: 10.1016/j.cmet.2017.03.021.
  33. Duggan BM, Singh AM, Chan DY, Schertzer JD. Postbiotics engage IRF4 in adipocytes to promote sex-dependent changes in blood glucose during obesity. Physiol Rep. 2022;10:e15439. doi: 10.14814/phy2.15439.
  34. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519:92–6. doi: 10.1038/nature14232.
  35. Lee J, Park S, Oh N, Park J, Kwon M, Seo J, et al. Oral intake of Lactobacillus plantarum L-14 extract alleviates obesity-associated disorders. Cell Prolif. 2021;54:e13039. doi: 10.1111/cpr.13039.
  36. Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, et al. Acetate and propionate stimulate adipogenesis via GPCR43. Endocrinology. 2005;146:5092–9. doi: 10.1210/en.2005-0545.
  37. Aranaz P, Romo-Hualde A, Zabala M, Navarro-Herrera D, Ruiz de Galarreta M, Gil AG, et al. Freeze-dried strawberry and blueberry attenuate diet-induced obesity. Food Funct. 2017;8:3999–4013. doi: 10.1039/C7FO00996H.
  38. Alard J, Cudennec B, Boutillier D, Peucelle V, Descat A, Decoin R, et al. Selection criteria for probiotic strains with obesity management potential. Nutrients. 2021;13:713. doi: 10.3390/nu13030713.
  39. Kim DE, Kim JK, Han SK, Jang SE, Han MJ, Kim DH. Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 alleviate inflammatory disorders in mice. J Med Food. 2019;22:1022–31. doi: 10.1089/jmf.2019.4419.
  40. Mistry RH, Liu F, Borewicz K, Lohuis MAM, Smidt H, Verkade HJ, et al. Long-term β-galacto-oligosaccharide supplementation decreases obesity and insulin resistance. Mol Nutr Food Res. 2020;64:e1900922. doi: 10.1002/mnfr.201900922.
  41. Isozaki S, Konishi H, Fujiya M, Tanaka H, Murakami Y, Kashima S, et al. Probiotic-derived polyphosphate accelerates intestinal epithelial wound healing. Mediators Inflamm. 2021;2021:5582943. doi: 10.1155/2021/5582943.
  42. Rodrigues e-Lacerda R, Fang H, Robin N, Bhatwa A, Marko DM, Schertzer JD. Microbiota and NOD-like receptors balance inflammation and metabolism. Biomed J. 2023;46:100610. doi: 10.1016/j.bj.2023.100610.
  43. Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. Synergistic stimulation of human monocytes by TLR4 and NOD agonists. Eur J Immunol. 2005;35:2459–70. doi: 10.1002/eji.200526286.
  44. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria improve high-fat-diet-induced diabetes in mice. Diabetologia. 2007;50:2374–83. doi: 10.1007/s00125-007-0791-0.
  45. Archer AC, Muthukumar SP, Halami PM. Lactobacillus fermentum MCC2759 and MCC2760 alleviate inflammation in diabetic rats. Probiotics Antimicrob Proteins. 2021;13:1068–80. doi: 10.1007/s12602-021-09744-0.
  46. Godkowicz M, Druszczyńska M. NOD1, NOD2 and NLRC5 receptors in antiviral and antimycobacterial immunity. Vaccines (Basel). 2022;10:1487. doi: 10.3390/vaccines10091487.
  47. Zhou YJ, Liu C, Li CL, Song YL, Tang YS, Zhou H, et al. Increased NOD1 activity in adipose tissue from patients with metabolic syndrome. Obesity (Silver Spring). 2015;23:1394–400. doi: 10.1002/oby.21113.
  48. Duggan BM, Tamrakar AK, Barra NG, Anhê FF, Paniccia G, Wallace JG, et al. Gut microbiota-based vaccination improves blood glucose control in obese mice. Mol Metab. 2022;55:101404. doi: 10.1016/j.molmet.2021.101404.
  49. Morrison HA, Trusiano B, Rowe AJ, Allen IC. Negative regulatory NLRs mitigate inflammation via NF-κB signaling. Biomed J. 2023;46:100616. doi: 10.1016/j.bj.2023.100616.
  50. Cheng D, Xu JH, Li JY, Wang SY, Wu TF, Chen QK, et al. Butyrate-ameliorated NLRC3 protects the intestinal barrier in a GPR43-dependent manner. Exp Cell Res. 2018;368:101–10. doi: 10.1016/j.yexcr.2018.04.018.
  51. Gomes Torres ACMB, Leite N, Tureck LV, de Souza RLR, Titski ACK, Milano-Gai GE, et al. Association between Toll-like receptors (TLR) and NOD-like receptor (NLR) polymorphisms and lipid and glucose metabolism. Gene. 2019;685:211–21. doi: 10.1016/j.gene.2018.11.065.
  52. Maslanik T, Tannura K, Mahaffey L, Loughridge AB, Benninson L, Ursell L, et al. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL-1β and IL-18 but not IL-6, IL-10 or MCP-1. PLoS One. 2012;7:e50636. doi: 10.1371/journal.pone.0050636.
  53. Li G, Yao W, Jiang H. Short-chain fatty acids enhance adipocyte differentiation in the stromal vascular fraction of porcine adipose tissue. J Nutr. 2014;144:1887–95. doi: 10.3945/jn.114.198531.
  54. Lin HV, Frassetto A, Kowalik EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via FFAR3-independent mechanisms. PLoS One. 2012;7:e35240. doi: 10.1371/journal.pone.0035240.
  55. Chakraborti CK. New-found link between microbiota and obesity. World J Gastrointest Pathophysiol. 2015;6:110. doi: 10.4291/wjgp.v6.i4.110.
  56. Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes (Lond). 2015;39:1331–8. doi: 10.1038/ijo.2015.84.
  57. Kundi ZM, Lee JCY, Pihlajamäki J, Chan CB, Leung KS, So SSY, et al. Dietary fiber from oat and rye brans ameliorate western diet–induced body weight gain and hepatic inflammation. Mol Nutr Food Res. 2021;65:e1900580. doi: 10.1002/mnfr.201900580.
  58. Ahmadi S, Nagpal R, Wang S, Gagliano J, Kitzman DW, Soleimanian-Zad S, et al. Prebiotics from acorn and sago prevent high-fat diet-induced insulin resistance. J Nutr Biochem. 2019;67:1–13. doi: 10.1016/j.jnutbio.2019.01.011.
  59. Pellonperä O, Mokkala K, Houttu N, Vahlberg T, Koivuniemi E, Tertti K, et al. Fish oil and/or probiotic intervention and gestational diabetes mellitus. Diabetes Care. 2019;42:1009–17. doi: 10.2337/dc18-2591.
  60. Thiennimitr P, Yasom S, Tunapong W, Chunchai T, Wanchai K, Pongchaidecha A, et al. Lactobacillus paracasei HII01, xylooligosaccharides, and synbiotics reduce gut disturbance in obese rats. Nutrition. 2018;54:40–7. doi: 10.1016/j.nut.2018.03.005.
  61. da Silva TF, Casarotti SN, de Oliveira GLV, Penna ALB. Impact of probiotics, prebiotics, and synbiotics on obese hosts. Crit Rev Food Sci Nutr. 2021;61:337–55. doi: 10.1080/10408398.2020.1733483.
  62. Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of probiotics and synbiotics on metabolic diseases. Int J Mol Sci. 2016;17:928. doi: 10.3390/ijms17060928.
  63. Vulevic J, Juric A, Tzortzis G, Gibson GR. Trans-galactooligosaccharides reduce markers of metabolic syndrome. J Nutr. 2013;143:324–31. doi: 10.3945/jn.112.166132.
  64. Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, et al. Metabolic adaptation to a high-fat diet and gut microbiota. Gut. 2012;61:543–53. doi: 10.1136/gutjnl-2011-301012.
  65. Woting A, Blaut M. The intestinal microbiota in metabolic disease. Nutrients. 2016;8:202. doi: 10.3390/nu8040202.
  66. Mithieux G. Gut microbiota and host metabolism. Neuroendocrinology. 2018;106:352–6. doi: 10.1159/000484526.
  67. Alard J, Lehrter V, Rhimi M, Mangin I, Peucelle V, Abraham AL, et al. Beneficial metabolic effects of selected probiotics. Environ Microbiol. 2016;18:1484–97. doi: 10.1111/1462-2920.13181.
  68. Balaguer F, Enrique M, Llopis S, Barrena M, Navarro V, Álvarez B, et al. Lipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1 reduces fat deposition. Microb Biotechnol. 2022;15:805–16. doi: 10.1111/1751-7915.13769.
  69. Foligné B, Dewulf J, Breton J, Claisse O, Lonvaud-Funel A, Pot B. Immunomodulation by Oenococcus oeni. Int J Food Microbiol. 2010;140:136–45. doi: 10.1016/j.ijfoodmicro.2010.04.007.
  70. Nakamura F, Ishida Y, Sawada D, Ashida N, Sugawara T, Sakai M, et al. Fragmented lactic acid bacterial cells ameliorate dyslipidemia. J Agric Food Chem. 2016;64:2549–59. doi: 10.1021/acs.jafc.5b05827.
  71. Wiciński M, Gębalski J, Gołębiewski J, Malinowski B. Probiotics for overweight and obesity. Microorganisms. 2020;8:1148. doi: 10.3390/microorganisms8081148.
  72. de Cossío LF, Fourrier C, Sauvant J, Everard A, Capuron L, Cani PD, et al. Impact of prebiotics in metabolic syndrome. Brain Behav Immun. 2017;64:33–49. doi: 10.1016/j.bbi.2016.12.022.
  73. Puiman P, Stoll B, Mølbak L, de Bruijn A, Schierbeek H, Boye M, et al. Antibiotics suppress urea production in neonatal pigs. Am J Physiol Gastrointest Liver Physiol. 2013;304:G300–9. doi: 10.1152/ajpgi.00229.2011.
  74. Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, et al. Roles of GPR41 and GPR43 in leptin secretion. FEBS Lett. 2010;584:2381–6. doi: 10.1016/j.febslet.2010.04.027.
  75. Vinderola G, Sanders ME, Salminen S. The concept of postbiotics. Foods. 2022;11:1077. doi: 10.3390/foods11081077.
  76. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979–84. doi: 10.1073/pnas.0605374104.
  77. Ji Y, Sun S, Shrestha N, Darragh LB, Shirakawa J, Xing Y, et al. TLR2 and TLR4 block pancreatic β-cell replication. Nat Immunol. 2019;20:677–86. doi: 10.1038/s41590-019-0396-z.
  78. Iori V, Iyer AM, Ravizza T, Beltrame L, Paracchini L, Marchini S, et al. Blockade of IL-1R1/TLR4 pathway in epilepsy. Neurobiol Dis. 2017;99:12–23. doi: 10.1016/j.nbd.2016.12.007.
  79. Bäckhed F, Normark S, Schweda EKH, Oscarson S, Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling. Microbes Infect. 2003;5:1057–63. doi: 10.1016/s1286-4579(03)00207-7.
  80. Dasu MR, Devaraj S, Park S, Jialal I. Increased TLR activation in type 2 diabetes. Diabetes Care. 2010;33:861–8. doi: 10.2337/dc09-1799.
  81. Berezow AB, Ernst RK, Coats SR, Braham PH, Karimi-Naser LM, Darveau RP. Differential innate immune responses to LPS. Microb Pathog. 2009;47:68–77. doi: 10.1016/j.micpath.2009.04.015.
  82. Esposito G, Pesce M, Seguella L, Lu J, Corpetti C, Del Re A, et al. Engineered Lactobacillus paracasei prevents colitis. Int J Mol Sci. 2021;22:2945. doi: 10.3390/ijms22062945.
  83. Gao H, Wen JJ, Hu JL, Nie QX, Chen HH, Xiong T, et al. Fermented Momordica charantia juice in diabetic rats. Food Res Int. 2019;121:367–78. doi: 10.1016/j.foodres.2019.03.055.
  84. Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Martinez JA. Diet, gut microbiota and obesity. Adv Nutr. 2019;10(Suppl 1):S17. doi: 10.1093/advances/nmy078.
  85. Kobyliak N, Falalyeyeva T, Tsyryuk O, Eslami M, Kyriienko D, Beregova T, et al. Strain-specific probiotic impacts on insulin resistance. J Diabetes Metab Disord. 2020;19:289–96. doi: 10.1007/s40200-020-00506-3.
  86. Kobyliak N, Falalyeyeva T, Beregova T, Spivak M. Probiotics for experimental obesity prevention. Endokrynol Pol. 2017;68:659–67. doi: 10.5603/ep.a2017.0055.
  87. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity. Diabetes. 2009;58:1509–17. doi: 10.2337/db08-1637.
  88. Higashikawa F, Noda M, Awaya T, Danshiitsoodol N, Matoba Y, Kumagai T, et al. Pediococcus pentosaceus LP28 and obesity. Eur J Clin Nutr. 2016;70:582–7. doi: 10.1038/ejcn.2016.17.
  89. Rizzetto L, Fava F, Tuohy KM, Selmi C. Immune system, inflammation and gut microbiome. J Autoimmun. 2018;92:12–34. doi: 10.1016/j.jaut.2018.05.008.
  90. Tovar-Spinoza Z, Carter D, Ferrone D, Eksioglu Y, Huckins S. MRI-guided laser ablation for epilepsy. Childs Nerv Syst. 2013;29:2089–94. doi: 10.1007/s00381-013-2169-6.
  91. Stagi S, Lapi E, Seminara S, Pelosi P, Del Greco P, Capirchio L, et al. Policaptil Gel Retard® in obese children. Ital J Pediatr. 2015;41:109. doi : 10.1186/s13052-015-0109-7.
  92. Jeon J, Jang J, Park K. Calcium-rich foods and type 2 diabetes. Nutrients. 2019;11:31. doi: 10.3390/nu11010031.
  93. Bahmani F, Tajadadi-Ebrahimi M, Kolahdooz F, Mazouchi M, Hadaegh H, Jamal AS, et al. Synbiotic bread in type 2 diabetes. J Am Coll Nutr. 2016;35:506–13. doi: 10.1080/07315724.2015.1032443.
  94. Tang R, Li L. Modulation of SCFAs in type 2 diabetes. Can J Infect Dis Med Microbiol. 2021;2021:6632266. doi: 10.1155/2021/6632266.
  95. Huang L, Thonusin C, Chattipakorn N, Chattipakorn SC. Gut microbiota and gestational diabetes. Eur J Nutr. 2021;60:2343–60. doi: 10.1007/s00394-021-02483-6.
  96. Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N. Lipopolysaccharide, inflammation and insulin action. PLoS One. 2013;8:e63983. doi: 10.1371/journal.pone.0063983.
  97. Carrizales-Sánchez AK, García-Cayuela T, Hernández-Brenes C, Senés-Guerrero C. Gut microbiota and metabolic syndrome in pediatrics. Gut Microbes. 2021;13:1960135. doi: 10.1080/19490976.2021.1960135.
  98. Xiong Y, Khlif MS, Egorova-Brumley N, Brodtmann A, Stark BC. Neural correlates of verbal fluency after stroke. Neuroimage Clin. 2023;38:103406. doi: 10.1016/j.nicl.2023.103406.
  99. Barra NG, Henriksbo BD, Anhê FF, Schertzer JD. NLRP3 inflammasome and adipose metabolism. Biochem J. 2020;477:1089–107. doi: 10.1042/bcj20190472.
  100. Heilbronn L, Campbell L. Adipose tissue macrophages and insulin resistance. Curr Pharm Des. 2008;14:1225–30. doi: 10.2174/138161208784246153.
  101. López-Alarcón M, Martínez-Coronado A, Velarde-Castro O, Rendón-Macías E, Fernández J. n-3 PUFA supplementation in obese children. Arch Med Res. 2011;42:502–8. doi: 10.1016/j.arcmed.2011.06.010.
  102. Yuan X, Chen R, Zhang Y, Lin X, Yang X, McCormick KL. Gut microbiota of Chinese obese children. Front Endocrinol (Lausanne). 2021;12:636272. doi: 10.3389/fendo.2021.636272.
  103. Balaguer F, Enrique M, Llopis S, Barrena M, Navarro V, Álvarez B, et al. Lipoteichoic acid from B. animalis subsp. lactis BPL1. Microb Biotechnol. 2022;15:805–16. doi: 10.1111/1751-7915.13769.
  104. Zhang Z, Zhou Z, Li Y, Zhou L, Ding Q, Xu L. Exopolysaccharides from Lactobacillus rhamnosus GG and adipogenesis. Sci Rep. 2016;6:36083. doi: 10.1038/srep36083.
  105. Park SJ, Sharma A, Lee HJ. Postbiotics against obesity. Int J Mol Sci. 2023;24:6414. doi: 10.3390/ijms24076414.
  106. Mao QQ, Li BY, Meng JM, Gan RY, Xu XY, Gu YY, et al. Tea extracts and NAFLD in mice. Food Sci Nutr. 2021;9:2954–67. doi: 10.1002/fsn3.2255.
  107. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High-fat diet, gut microbiota and TLR4 signaling. PLoS One. 2012;7:e47713. doi: 10.1371/journal.pone.0047713.
  108. Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, et al. Sodium butyrate and steatohepatitis. World J Gastroenterol. 2017;23:60–75. doi: 10.3748/wjg.v23.i1.60.
  109. Seo KH, Lee HG, Eor JY, Jeon HJ, Yokoyama W, Kim H. Kefir-derived postbiotics and obesity. Food Res Int. 2022;157:111445. doi: 10.1016/j.foodres.2022.111445.
  110. Ke X, Walker A, Haange SB, Lagkouvardos I, Liu Y, Schmitt-Kopplin P, et al. Synbiotic-driven metabolic improvement. Mol Metab. 2019;22:96–109. doi: 10.1016/j.molmet.2019.01.012.
  111. Khanna S, Walia S, Kondepudi KK, Shukla G. Indigenous probiotics and metabolic syndrome. Antonie Van Leeuwenhoek. 2020;113:1345–59. doi: 10.1007/s10482-020-01445-y.
  112. Ménard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M. Anti-inflammatory metabolites of lactic acid bacteria. Gut. 2004;53:821–8. doi: 10.1136/gut.2003.026252.
  113. Fiore G, Magenes VC, Di Profio E, Milanta C, Calcaterra V, Diamanti A, et al. Gut microbiota in pediatric obesity. Minerva Pediatr. 2022;74:632–49. doi: 10.23736/s2724-5276.22.06964-6.
  114. Calcaterra V, Cena H, Pelizzo G, Porri D, Regalbuto C, Vinci F, et al. Bariatric surgery in adolescents. Children (Basel). 2021;8:453. doi: 10.3390/children8060453.
  115. Scaglioni S, Verduci E, Salvioni M, Bruzzese MG, Radaelli G, Zetterström R, et al. Plasma fatty acids and obesity in children. Acta Paediatr. 2006;95:964–9. doi: 10.1080/08035250600764834.
  116. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity clinical practice guideline. J Clin Endocrinol Metab. 2017;102:709–57. doi: 10.1210/jc.2016-2573.
  117. Wade WG, Prosdocimi EM. Profiling of oral bacterial communities. J Dent Res. 2020;99:621–9. doi: 10.1177/0022034520914594.
  118. Wilkins AT, Reimer RA. Obesity, early-life gut microbiota and antibiotics. Microorganisms. 2021;9:413. doi: 10.3390/microorganisms9020413.
Ahead of Print Subscription Review Article
Volume 03
01
Received 25/12/2025
Accepted 28/01/2026
Published 07/02/2026
Publication Time 44 Days
115

Login


My IP

PlumX Metrics